サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1575747

脊柱後弯症治療市場：2024年～2031年

Kyphosis Treatment Market - 2024-2031

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
脊柱後弯症治療市場：2024年～2031年
出版日: 2024年10月22日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

脊柱後弯症治療の世界市場は、2023年に13億米ドルに達し、2024～2031年の予測期間中にCAGR 6.2%で成長し、2031年には21億米ドルに達すると予測されています。

脊柱後弯症は背骨の湾曲であり、背中の上部が通常よりも丸く見えます。背中の痛みや筋肉のこわばりを引き起こす可能性があります。非外科的治療と外科的治療の選択肢があります。

脊柱後弯症は、若者から高齢者までがかかる可能性があります。脊柱後弯症はさまざまな問題によって引き起こされ、患者さんによって影響も異なります。脊柱後弯症は、脊椎の退行性疾患（関節炎や椎間板変性など）や骨粗鬆症による骨折（骨粗鬆症性圧迫骨折）、怪我（外傷）によって引き起こされることがあります。

市場力学：

促進要因と阻害要因

治療オプションの進歩

理学療法、装具、疼痛管理技術は、非侵襲的な治療を好む患者に実用的な選択肢を提供するために進化しており、その結果、治療分野全体が拡大しています。幹細胞治療や多血小板血漿（PRP）注射のような生物学的進歩は、損傷した組織を治癒・再生させ、脊柱後弯症患者にとってより良い結果をもたらします。

脊柱のアライメントを特に促進することを目的とした革新的な整形外科器具や装具の開発は、治療効果と患者の快適性を向上させ、その結果、その使用を後押しします。脊柱後弯症に対する個別化された治療アプローチは、管理の改善、より高い患者満足度、より良い転帰をもたらします。

認識不足

症状や利用可能な治療オプションに関する認識不足は、市場の成長と拡大の妨げになると予想されます。患者は、外科的治療と非外科的治療の両方について、利用可能な治療選択肢を知らない可能性があり、その結果、生活の質を改善できる効果的な治療法が十分に利用されていないです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 治療オプションの進歩
    • 抑制要因
      • 認知度の欠如
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • 特許分析
  • SWOT分析
  • DMIオピニオン

第6章 タイプ別

  • 姿勢性後弯症
  • ショイエルマン後弯症
  • 先天性後弯症

第7章 治療タイプ別

  • 薬剤
    • アスピリン
    • イブプロフェン
    • ナプロキセン
    • アセトアミノフェン
    • その他
  • デバイス
  • その他

第8章 流通チャネル別

  • 病院薬局
  • オンライン薬局
  • 小売薬局
  • その他

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第11章 企業プロファイル

  • Salo Orthotics
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • AdvaCare Pharma
  • Boston Orthotics & Prosthetics
  • ScoliBrace
  • ALIMCO
  • NuVasive, Inc.
  • Stryker Corporation
  • Mallinckrodt Pharmaceuticals
  • Wellona Pharma
  • Bayer AG.

第12章 付録

目次
Product Code: PH4997

Overview

Global Kyphosis Treatment Market reached US$ 1.3 billion in 2023 and is expected to reach US$ 2.1 billion by 2031, growing at a CAGR of 6.2% during the forecast period 2024-2031.

Kyphosis is the curvature of the spine that causes the top of the back to appear more rounded than normal. It might cause back pain and stiff muscles. There are nonsurgical and surgical treatment options available.

Kyphosis can affect the young and the old. It is brought on by different problems and can affect each patient differently. Kyphosis can be caused by degenerative diseases of the spine (such as arthritis or disk degeneration) as well as fractures caused by osteoporosis (osteoporotic compression fractures) and injury (trauma).

Market Dynamics: Drivers & Restraints

Advancements in treatment options

Physical therapy, bracing, and pain management techniques have evolved to give practical alternatives for patients who prefer non-invasive treatments, therefore expanding the entire therapeutic field. Biologic advancements such as stem cell therapy and platelet-rich plasma (PRP) injections can heal and regenerate tissues that have been damaged, resulting in better outcomes for kyphosis patients.

The development of innovative orthopedic devices and braces intended specifically to promote spinal alignment can improve therapy efficacy and patient comfort, hence boosting their use. Personalized treatment approaches for kyphosis result in improved management, higher patient satisfaction, and better outcomes.

Lack of awareness

Lack of awareness about the condition as well as the available treatment options is expected to hinder market growth and expansion. Patients might be unaware of the available treatment alternatives, both surgical and non-surgical, resulting in the underuse of effective therapies that could improve their quality of life.

Segment Analysis

The global kyphosis treatment market is segmented based on type, treatment type, distribution channel and region.

Scheuermann's kyphosis segment is expected to dominate the market share

The Scheuermann kyphosis segment holds a major portion of the market share and is anticipated to continue this trend during the forecast period. This is attributed to the increase in the geriatric population and incidences of the Scheuermann kyphosis diseases. Scheuermann's kyphosis (kye-FOH-sis) is an upper back condition. It gives the upper back a rounded appearance, giving the appearance of being hunched over. Scheuermann's disease is another name for it.

For instance, according to the report published by the National Institute of Health in 2023, it is stated that the prevalence of the disease in the United States is 1% to 8%. This increasing incidence is expected to contribute to the overall market growth. Increasing Scheuermann's kyphosis increases the demand for the treatment of the disease

Geographical Analysis

North America is expected to hold a significant position in the kyphosis treatment market share

North America is anticipated to dominate the kyphosis treatment market, globally. The factors attributed to the high growth of the region are the increasing number of kyphosis cases, increase in technological advancement, increase in genetic disorders and increase in geriatric population.

For instance, according to the report published by the National Institute of Health in 2023, it is stated that Scheuermann's Kyphosis (SK) is a rigid spinal kyphosis, which can occur the most and can contribute to the regional market expansion.

In addition, increasing strategies such as mergers and acquisitions and partnerships within key market players are expected to strengthen their product portfolio which will drive the market. Also, several product launches in the market will lead to lucrative growth of the market.

Market Segmentation

By Type

  • Postural Kyphosis
  • Scheuermann's Kyphosis
  • Congenital Kyphosis

By Treatment Type

  • Drugs
    • Aspirin
    • Ibuprofen
    • Naproxen
    • Acetaminophen
    • Others
  • Devices
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the market include Salo Orthotics, AdvaCare Pharma, Boston Orthotics & Prosthetics, ScoliBrace, ALIMCO, NuVasive, Inc., Stryker Corporation, Mallinckrodt Pharmaceuticals, Wellona Pharma and Bayer AG among others.

Why Purchase the Report?

  • To visualize the global kyphosis treatment market segmentation based on type, treatment type, distribution channel, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of kyphosis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global kyphosis treatment market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancements in treatment options
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of awareness
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Postural Kyphosis*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Scheuermann's Kyphosis
  • 6.4. Congenital Kyphosis

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Drugs*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Aspirin
    • 7.2.4. Ibuprofen
    • 7.2.5. Naproxen
    • 7.2.6. Acetaminophen
    • 7.2.7. Others
  • 7.3. Devices
  • 7.4. Others

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
      • 9.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
      • 9.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
      • 9.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.3.1. The U.S.
      • 9.2.3.2. Canada
      • 9.2.3.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
      • 9.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
      • 9.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.4.1. Germany
      • 9.3.4.2. UK
      • 9.3.4.3. France
      • 9.3.4.4. Italy
      • 9.3.4.5. Spain
      • 9.3.4.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
      • 9.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
      • 9.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.4.1. Brazil
      • 9.4.4.2. Argentina
      • 9.4.4.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
      • 9.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
      • 9.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.4.1. China
      • 9.5.4.2. India
      • 9.5.4.3. Japan
      • 9.5.4.4. South Korea
      • 9.5.4.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
      • 9.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
      • 9.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Salo Orthotics*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. AdvaCare Pharma
  • 11.3. Boston Orthotics & Prosthetics
  • 11.4. ScoliBrace
  • 11.5. ALIMCO
  • 11.6. NuVasive, Inc.
  • 11.7. Stryker Corporation
  • 11.8. Mallinckrodt Pharmaceuticals
  • 11.9. Wellona Pharma
  • 11.10. Bayer AG.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us